La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Greenwich LifeSciences Gestion
Gestion contrôle des critères 1/4
Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.
Informations clés
Snehal Patel
Directeur général
US$2.8m
Rémunération totale
| Pourcentage du salaire du PDG | 20.2% |
| Durée du mandat du directeur général | 14.5yrs |
| Propriété du PDG | 42.1% |
| Durée moyenne d'occupation des postes de direction | pas de données |
| Durée moyenne du mandat des membres du conseil d'administration | 14.5yrs |
Mises à jour récentes de la gestion
Recent updates
We Think Greenwich LifeSciences (NASDAQ:GLSI) Can Afford To Drive Business Growth
Aug 22
Greenwich LifeSciences: Trying To Move A Needle That Doesn't Like To Budge
Jun 26Here's Why We're Not Too Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Situation
Jan 12We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate
Jan 29Greenwich LifeSciences: Persevering CEO And Interesting Data
Sep 06Greenwich LifeSciences halts stock buyback program
Jul 11Greenwich LifeSciences: A First Look
May 19Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential
Apr 21Companies Like Greenwich LifeSciences (NASDAQ:GLSI) Are In A Position To Invest In Growth
Feb 01We Think Greenwich LifeSciences (NASDAQ:GLSI) Can Afford To Drive Business Growth
Sep 30We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate
Apr 04Are Insiders Buying Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock?
Feb 16
What Is The Ownership Structure Like For Greenwich LifeSciences, Inc. (NASDAQ:GLSI)?
Dec 25Greenwich LifeSciences: Optimism On 'GP2' Breast Cancer Immunotherapy Candidate
Dec 23Greenwich LifeSciences under stress on pricing upsized $26.4M equity offering
Dec 18Greenwich LifeSciences inks deal with Westport Bio for pre-clinical coronavirus vaccine candidates
Dec 15Greenwich LifeSciences trebles in value as breast cancer therapy shines in mid-stage trial
Dec 09Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$10m |
| Mar 31 2024 | n/a | n/a | -US$9m |
| Dec 31 2023 | US$3m | US$557k | -US$9m |
| Sep 30 2023 | n/a | n/a | -US$9m |
| Jun 30 2023 | n/a | n/a | -US$9m |
| Mar 31 2023 | n/a | n/a | -US$8m |
| Dec 31 2022 | US$2m | US$506k | -US$8m |
| Sep 30 2022 | n/a | n/a | -US$7m |
| Jun 30 2022 | n/a | n/a | -US$6m |
| Mar 31 2022 | n/a | n/a | -US$6m |
| Dec 31 2021 | US$1m | US$450k | -US$5m |
| Sep 30 2021 | n/a | n/a | -US$3m |
| Jun 30 2021 | n/a | n/a | -US$3m |
| Mar 31 2021 | n/a | n/a | -US$2m |
| Dec 31 2020 | US$999k | US$115k | -US$2m |
| Sep 30 2020 | n/a | n/a | -US$1m |
| Jun 30 2020 | n/a | n/a | -US$1m |
| Mar 31 2020 | n/a | n/a | -US$4m |
| Dec 31 2019 | US$139k | n/a | -US$3m |
Rémunération vs marché: La rémunération totale de Snehal ($USD 2.75M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 1.54M ).
Rémunération et revenus: La rémunération de Snehal a augmenté alors que l'entreprise n'est pas rentable.
PDG
Snehal Patel (60 yo)
14.5yrs
Titularisation
US$2,750,029
Compensation
Mr. Snehal S. Patel has been Chief Executive Officer of Greenwich Lifesciences Inc. since June 2016 and has been Chief Financial Officer and Director since February 2010. He serves as Managing Director at...
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, CFO & Director | 14.5yrs | US$2.75m | 42.11% $ 81.9m | |
| Founder & Independent Director | 18yrs | US$65.64k | 2.38% $ 4.6m | |
| Chief Medical Officer & Director | 4.9yrs | pas de données | 0.69% $ 1.3m | |
| Independent Chairman of the Board | 15.5yrs | US$98.39k | 4.72% $ 9.2m | |
| Independent Director | 4.9yrs | US$65.64k | 3.02% $ 5.9m |
14.5yrs
Durée moyenne de l'emploi
73yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration GLSI sont chevronnés et expérimentés (durée moyenne d'administration 14.5 ans).